NASDAQ · MRK
Healthcare · Drug Manufacturers - General
$150.91
Down-$2.81 (-1.86%)
Updated Sep 23, 2026, 11:56 PM
SID Score
8.6/10
Composite research score
Smart Money
55/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MRK closed at $150.91 after 20 trading sessions, down 3.54% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $148.69 | $153.57 | $148.04 | $150.91 | 11.17M |
| Sep 21, 2026 | $146.785 | $150.49 | $145.60 | $149.50 | 8M |
| Sep 18, 2026 | $147.08 | $147.84 | $145.74 | $146.87 | 31.16M |
| Sep 17, 2026 | $145.74 | $147.65 | $145.323 | $147.15 | 11.06M |
| Sep 16, 2026 | $143.96 | $144.97 | $143.50 | $144.91 | 7.23M |
| Sep 15, 2026 | $143.85 | $144.15 | $142.32 | $143.79 | 8.29M |
| Sep 14, 2026 | $146.42 | $147.09 | $144.10 | $144.85 | 7.41M |
| Sep 11, 2026 | $145.52 | $145.90 | $143.68 | $143.93 | 8.68M |
| Sep 10, 2026 | $147.94 | $148.00 | $144.10 | $144.71 | 7.54M |
| Sep 9, 2026 | $148.96 | $149.41 | $147.18 | $147.53 | 8.55M |
| Sep 8, 2026 | $148.41 | $149.60 | $146.281 | $148.46 | 11.19M |
| Sep 4, 2026 | $150.83 | $152.22 | $150.085 | $150.33 | 4.4M |
| Sep 3, 2026 | $152.80 | $152.80 | $148.90 | $152.34 | 6.5M |
| Sep 2, 2026 | $151.50 | $152.69 | $149.97 | $151.64 | 8.97M |
| Sep 1, 2026 | $150.23 | $151.6776 | $148.55 | $149.86 | 9.87M |
| Aug 31, 2026 | $147.00 | $148.689 | $145.95 | $147.76 | 11.13M |
| Aug 28, 2026 | $146.72 | $149.0078 | $145.75 | $148.35 | 8.07M |
| Aug 27, 2026 | $149.53 | $152.08 | $149.02 | $149.54 | 8.53M |
| Aug 26, 2026 | $154.35 | $155.19 | $152.6109 | $153.10 | 8.63M |
| Aug 25, 2026 | $151.00 | $156.9199 | $150.66 | $156.45 | 14.01M |
The latest Smart Investors Daily articles mentioning MRK.
MRK research
Company profile and research snapshot.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | Guggenheim | Buy | — |
| Sep 4, 2026 | Wells Fargo | Overweight | — |
| Aug 25, 2026 | Wolfe Research | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office
Yahoo · Sep 23, 2026
When patients experience prolonged diarrhea and abdominal pain, one condition doctors may consider is inflammatory bowel disease (IBD). In IBD, different parts of the gastrointestinal tract become inflamed, often causing recurring abdominal pain and diarrhea. If left untreated, the inflammation from IBD can lead to serious complications.
Yahoo · Sep 23, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.
SeekingAlpha · Sep 23, 2026
Lipfendra and promising intismeran autogene trial results support Merck's multi-year portfolio renewal prospects amid patent cliff risks. Read why MRK is a Hold.
Interpretive context generated from the platform’s current data sources.
Merck & Co. shares closed at $150.92, declining 2.49% in the most recent session, per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum over longer timeframes, gaining 29.46% over the trailing three months and 49.11% over the past year. The stock trades well above key moving averages, sitting 9.05% above its 50-day moving average of $138.39 and 22.82% above its 200-day moving average of $122.87, according to Massive/Polygon technical data. The 14-day relative strength index reads 54.1, placing the stock in neutral territory and suggesting neither overbought nor oversold conditions. Merck carries a beta of 0.299, indicating significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 13.4 million shares, reflecting robust liquidity. The company's market capitalization currently totals approximately $248.8 billion, positioning it among the largest healthcare firms globally.
Merck & Co. trades at a price-to-earnings ratio of 12.99, which sits below the broader S&P 500 average, per SID market data. The company's PEG ratio of 0.79 falls below the commonly referenced fair-value threshold of 1.0, suggesting the stock's earnings growth rate is favorable relative to its current P/E multiple. According to SEC filings, the price-to-book ratio stands at 4.77, reflecting a premium to book value consistent with pharmaceutical companies that carry significant intangible asset portfolios. The dividend yield registers at 3.27%, providing meaningful income relative to the healthcare sector median. Operating within the healthcare sector, Merck's valuation profile reflects both defensive characteristics and growth considerations tied to its drug pipeline. The combination of a sub-13 P/E, a PEG ratio below 1.0, and a dividend yield exceeding 3% presents a quantitative valuation profile distinct among large-cap pharmaceutical peers.
Merck & Co. carries a composite smart money score of 55 out of 100, reflecting a neutral overall signal, per SID market data. Institutional activity scores a perfect 25 out of 25, indicating strong conviction from large fund managers and consistent accumulation patterns in recent filings. In contrast, the insider trading component scores just 9.0 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days — comprising 4 purchases and 16 sales. The sell-to-buy ratio of 4-to-1 among insiders warrants monitoring, though executive stock sales frequently reflect pre-planned disposition schedules rather than directional sentiment. Dark pool activity registers at 8.5 out of 25, suggesting limited notable activity in off-exchange venues. Congressional trading activity scores 12 out of 25, reflecting moderate engagement from elected officials disclosed through required filings. The divergence between maximum institutional conviction and lower insider scores creates the neutral composite reading for Merck.
Merck & Co.'s most recently reported quarter, dated April 30, showed an actual loss of $1.28 per share against an analyst estimate of negative $1.48, representing a positive surprise of $0.20, according to company earnings reports. The prior reported quarter, dated August 4, reflected a loss of $0.13 per share versus an estimate of $0.23, constituting a negative surprise of $0.36 per analyst estimates. Upcoming quarterly reports are scheduled for April 23, with consensus expectations calling for a loss of $1.01 per share, and July 28, where analysts project a loss of $0.30 per share. The negative EPS figures across multiple quarters reflect significant charges or adjustments that weigh on reported earnings. Analysts tracking the company continue to calibrate forward estimates as Merck navigates pipeline investments and potential restructuring-related costs that impact near-term bottom-line results.
Wall Street consensus on Merck & Co. remains uniformly positive, with all five most recent analyst actions reaffirming bullish ratings, per SID consensus data. On September 10, HSBC maintained its Buy rating, followed by Leerink Partners reiterating Outperform on September 9, and Guggenheim sustaining its Buy recommendation on September 8. Wells Fargo maintained an Overweight rating on September 4, while Wolfe Research reiterated Outperform on August 25, according to Wall Street analyst reports. Notably, none of the five most recent rating actions represented upgrades or downgrades — each firm held its prior positive stance unchanged, reflecting sustained conviction in Merck's fundamental trajectory. The absence of any Hold, Underweight, or Sell ratings among recent coverage updates underscores broad institutional analyst alignment. The clustering of reaffirmations within a three-week window suggests coordinated reassessment timing, potentially linked to recent clinical data readouts or pipeline developments that reinforced existing investment theses across multiple firms.
The latest Smart Investors Daily articles mentioning MRK.
